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Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature
hematopoietic precursors known to suppress immune responses in infection, chronic
inﬂammation, cancer, and autoimmunity. In this paper, we review recent ﬁndings detailing
their mode of action and discuss recent reports that suggest that MDSC are also expanded
during transplantation and that modulation of MDSC can participate in preventing graft
rejection as well as graft-versus-host disease.
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INTRODUCTION
In the 1980s, a new cell population known as natural suppressor
cells, distinct fromT andNK cells, was described in tumor-bearing
mice (Strober, 1984; Maier et al., 1989). Generated in bone mar-
row under the inﬂuence of soluble factors produced by tumors,
these cells derive from a mixed and heterogeneous population
of myeloid cells found at different differentiation stages. They
have been deﬁned as myeloid suppressive cells because of their
ability to suppress immune responses (Bronte et al., 1998, 1999,
2000). Tominimize the confusionwith existingmesenchymal stem
cells, Gabrilovich (2007) proposed to name these cells “myeloid-
derived suppressor cells” (MDSC). In mice, MDSC accumulate
in the lymphatic organs (Ezernitchi et al., 2006) after the devel-
opment of various diseases such as infections (Marshall et al.,
2001; Goni et al., 2002; Mencacci et al., 2002), chronic inﬂam-
mation, tumor growth, graft-versus-host disease (GVHD; Bobe
et al., 1999) and immune stress due to superantigen stimulation
(staphylococcal endotoxin A, SEA; Cauley et al., 2000). In mice,
MDSC are characterized by the expression of myeloid cell mark-
ers, such as GR-1 (Ly6G and Ly6C) and CD11b (Bronte et al.,
1998), as well as immature cell markers, such as CD31 (Bronte
et al., 2000). Two subsets of MDSC were also described: mono-
cytic MDSC, which have CD11b+Ly6G−Ly6CHigh phenotype,
and granulocytic MDSC, which have CD11b+Ly6G+Ly6C+/−
phenotype (Movahedi et al., 2008; Youn et al., 2008). Other
markers correlated to their suppressive function have been iden-
tiﬁed as CD80 (Mencacci et al., 2002), CD115 (Huang et al.,
2006), or CD16 (Marshall et al., 2001). They also express
MHC class I molecules, but not MHC class II molecules
(Gabrilovich et al., 2001). In humans, MDSC accumulate in can-
cer patients (Pak et al., 1995; Almand et al., 2001) and are deﬁned
by the expression of immature markers such as CD34, CD33,
CD15, and CD16. Moreover, CD14+HLA-DR−/low MDSC have
been recently characterized in cancer patients (Hoechst et al.,
2008), suggesting that as is the case with mice, various human
tumors induce different MDSC subsets. In the presence of
appropriate growth factors [IL-4 + granulocyte macrophage
colony-stimulating factor (GM-CSF) or TNF-α + GM-CSF],
MDSC can differentiate into efﬁcient antigen-presenting cells
(APC), either DC or macrophages by increasing the expres-
sion of costimulatory molecules and MHC class II molecules
(Bronte et al., 2000; Li et al., 2004).
CONTROL OF MDSC BY CYTOKINES
Many studies have shown that inﬂammatory environments induce
the production and the accumulation of MDSC able to block
CD4 and CD8- immune responses and lead to cancer develop-
ment. Indeed, tumor cells secrete a large variety of cytokines
that allow the recruitment of MDSC in lymphoid organs or
peripheral blood and direct their differentiation into suppressor
cells (Kusmartsev et al., 2003). That global inﬂammation controls
MDSC recruitment is best illustrated by observations showing
that the reduction of inﬂammatory potential in IL-1R−/− mice
allows delaying MDSC accumulation and then reducing tumor
and metastatic growth (Bunt et al., 2007; Figure 1). One key
factor controlling MDSC expansion and the development of can-
cer is peroxisome proliferator-activated receptor-gamma (PPARγ;
Wu et al., 2012). Also vascular endothelial growth factor (VEGF;
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FIGURE 1 | Control of MDSC by cytokines. (A) Inﬂammatory
environments lead to expansion of MDSC by activation of the STAT3
signaling pathway by several factors including granulocyte macrophage
colony-stimulating factor (GM-CSF; Bronte et al., 1999); macrophage
colony-stimulating factor (M-CSF; Kusmartsev et al., 2003); IL-6 (Bunt et al.,
2007); peroxisome proliferator-activated receptor-gamma (PPARγ; Wu et al.,
2012); vascular endothelial growth factor (VEGF; Ohm and Carbone, 2001;
Melani et al., 2003); stem cell factor (SCF; Mellstedt et al., 1999); IL-13
(Gallina et al., 2006); Hps72 (Chalmin et al., 2010); and fms-like tyrosine
kinase 3 ligand (Flt3L; Solheim et al., 2007). Agonists of the COX2
pathway also result in expansion of MDSC, including prostaglandin
E2 (PGE2), lipopolysaccharide (LPS), IL-1β, and IFN-γ (Obermajer et al., 2011).
The complement anaphylatoxin C5a is also described to induce MDSC
(Markiewski et al., 2008). (B) Blockade of SCF/c-kit interaction or SCF
blockade by siRNA reduce MDSC expansion (Mellstedt et al., 1999).
The combination of IL-4 and GM-CSF inhibits MDSC function by
inducing their differentiation into mature DC (Bronte et al., 1999;
Sinha et al., 2007a).
Melani et al., 2003), macrophage colony-stimulating factor
(M-CSF; Kusmartsev et al., 2003) or IL-6 (Bunt et al., 2007) are
required for MDSC expansion (Ohm and Carbone, 2001). Indeed,
they prevent MDSC differentiation into mature DC through a
mechanism involving the activation of STAT3 signaling path-
way (Gabrilovich, 2004; Nefedova et al., 2004). By contrast, in
a mouse cancer model, the use of siRNA blocking expression
of stem cell factor (SCF) or blockade of SCF/c-kit receptor
interaction allowed to reduce MDSC expansion and restore T lym-
phocyte proliferation, thus resulting in tumor rejection (Pan et al.,
2008). GM-CSF also induces MDSC expansion which suppresses
tumor-speciﬁc CD8+ T cell response. However, in combination
with IL-4, GM-CSF induces MDSC differentiation into mature
DC capable to activate immune responses (Bronte et al., 1999;
Mellstedt et al., 1999). PGE2 also, as well as other COX2 activators
as lipopolysaccharide, IL-1β, and IFN-γ, by inducing expression
of COX2 in monocytes, blocks their differentiation into mature
DCs and induces a typical MDSC phenotype (Sinha et al., 2007a;
Obermajer et al., 2011). In addition IFN-γ produced by T cells
in tumor-bearing mice was shown to make MDSC responsive to
IL-13 and suppressive (Gallina et al., 2006). Another important
factor is Hsp72 that was shown essential for expansion, activa-
tion, and suppressive function of murine and human MDSC,
also through STAT3 signaling pathway (Chalmin et al., 2010).
Another study demonstrated that injection of fms-like tyrosine
kinase 3 ligand (Flt3L) encoding adenoviruses in tumor-bearing
mice resulted in the increase of spleen DC, T, B lymphocytes
and NK cells but also of MDSC which dominated and blocked
anti-tumor activity of effector cells (Solheim et al., 2007). Finally,
it was recently shown that the complement anaphylatoxin C5a
increases tumor inﬁltrating MDCS and gives them a suppressive
activity through reactive oxygen species (ROS) and reactive nitro-
gen species (RNS) regulation (Markiewski et al., 2008). Several
tumor-derived factors such as TGF-β, IL-3, IL-6, IL-10, platelet-
derived growth factors, and GM-CSF could also induce ROS
production by MDSC (Sauer et al., 2001). Beside soluble factors,
MDSC are controlled by their expression of Fas which leads to
cell apoptosis after contact with Fas-L positive activated T cells
(Sinha et al., 2011).
MECHANISMS OF SUPPRESSION
Several regulatory mechanisms have been associated to MDSC
and new ones are being uncovered (summarized in Figure 2), a
phenomenon probably due to their heterogeneity. Following an
immune stress due to GM-CSF production by tumor cells, MDSC
accumulate in lymphoid organs where they suppress proliferation
of and cytokine production by T and B cells activated by alloanti-
gens (Schmidt-Wolf et al., 1992) or by CD3 stimulation (Young
et al., 1996). Indeed,MDSCblock the cell cycle at theG0/G1phases
in a contact-dependent manner (Gabrilovich, 2004; Kusmartsev
et al., 2004). The suppressive activity of MDSC also depends on the
release of IFN-γ by target T cells (Mazzoni et al., 2002). MDSC can
also inhibit NK cell activity through membrane-bound TGF-β1,
resulting in inhibition of IFN-γ and NKG2D expression (Li et al.,
2009). The effect shows a high efﬁcacy since addition in vitro of
only 3% of MDSC was able to completely block T cell proliferation
(Mazzoni et al., 2002). To control T cell response and in response
to signals provided by activated T cells, activated MDSC use two
enzymes involved in L-arginine metabolism: iNOS which allows
NO generation (Kusmartsev et al., 2000) and arginase 1 (Arg1)
which depletes arginine from the environment (Mills et al., 1992;
Bronte and Zanovello, 2005; Gallina et al., 2006). These two mech-
anisms of action appear to be used by monocytic and granulocytic
subtypes of MDSC, respectively (Movahedi et al., 2008). In vitro,
iNOS inhibitors (L-NMMA) combinedor notwithArg1 inhibitors
(Kusmartsev et al., 2000; Bronte et al., 2005) block inhibition of
T cells by MDSC. Similarly, phosphodiesterase-5 inhibitors delay
tumor progression by decreasing Arg1 and iNOS expression and
by regulating the suppressive machinery of MDSC. The activation
of either of these enzymes inhibits T cell proliferation by interfer-
ing with the transduction of intracellular signals and by inducing
T cell apoptosis (Brito et al., 1999; Bronte et al., 2003). In fact,
Frontiers in Immunology | Alloimmunity andTransplantation July 2012 | Volume 3 | Article 208 | 2
“ﬁmmu-03-00208” — 2012/7/14 — 20:11 — page 3 — #3
Dilek et al. Myeloid-derived suppressor cells in transplantation
FIGURE 2 | Mechanisms of suppression by MDSC. (A) Arg1, arginase-1.
Arg1 induces arginine deprivation. iNOS, inducible nitric oxide synthase. iNOS
induces nitric oxide (NO) production (that can be derived into reactive
nitrogen species, RNS). Arg1 activity leads to CD3ζ down-modulation
(Rodriguez et al., 2007; Highﬁll et al., 2010), TCR CD3ζ nitrosylation (Nagaraj
et al., 2007, 2010), and natural Treg (nTreg) expansion (Seraﬁni et al., 2006,
2008), while iNOS activity leads toT cell apoptosis (Brito et al., 1999; Jia et al.,
2010) and inhibition of T cell proliferation (Rodriguez et al., 2007; Cripps et al.,
2010). (B) eNOS, endothelial nitric oxide synthase. NOX2, NADPH oxidase 2.
The enzyme induces reactive oxygen species (ROS) production and, together
with eNOS and/or iNOS activities, can induce RNS production. NOX2 leads to
inhibition of T cell proliferation through ROS production (Tacke and Kurts,
2011), TCR CD3ζ nitration (Nagaraj et al., 2010) and MHC class I nitration (Lu
et al., 2011). (C) HO-1, heme oxygenase 1. The enzyme leads to inhibition of
T cell proliferation probably through CO production (DeWilde et al., 2009).
(D) Cys, cysteine. Cys2, cystine. GSH, glutathione. MDSC compete with
dendritic cells (DCs) for Cys2 import from the extracellular milieu. This
prevents DCs from providing sufﬁcient Cys toT cells for GSH production, thus
inhibiting T cell proliferation (Srivastava et al., 2010). Dotted arrows show
physiological import/export inhibited by MDSC activity. (E) ADAM17, ADAM
metallopeptidase domain 17. ADAM17 activity leads to cleavage of L-selectin
(CD62L) ectodomain resulting in inhibition of the homing to lymph nodes and
sites of inﬂammation (Hanson et al., 2009). (F) Membrane-boundTGF-β1 leads
to NK cell anergy, resulting in inhibition of NKG2D and IFN-γ expression (Li
et al., 2009). TGF-β production leads to inhibition of cytotoxic T lymphocytes
(CTL; Terabe et al., 2003). In an IFN-γ rich environment, TGF-β plus IL-10 lead to
expansion of induced-Treg (iTreg; Huang et al., 2006). IL-10 production
promotesTh2 deviation and macrophage type 2 (Mϕ2) polarization that
secrete lower amounts of IL-12 and higher amounts of IL-10 (Sinha et al.,
2007b). Question marks denote suggested, but unproven, participations.
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the loss of L-arginine inhibits T cell proliferation through several
mechanisms such as the decrease of CD3ζ chain expression and
the inhibition of Cyclin D3 and Cyclin-dependent Kinase (cdk)-
4 upregulation (Rodriguez et al., 2002, 2004, 2007; Highﬁll et al.,
2010). Interestingly, arginine deprivation of T cells can reproduce
the activity of MDSC by blocking the cell cycle at the G0/G1 stage
(Rodriguez et al., 2002). Regulation of L-arginine concentration
in the microenvironment is therefore an important mechanism
to modulate CD3ζ chain expression of T cell receptor (TCR) and
T cell function. Another important consequence of Arg1 activity
is the induction of expansion of natural T regulatory cells (nTreg;
Seraﬁni et al., 2008). The second mechanism of action involv-
ing iNOS and NO production suppresses T cell function through
other mechanisms involving the inhibition of JAK3 and STAT5, a
mechanism shared with suppressive macrophages (Bingisser et al.,
1998), the inhibition of MHC class II expression (Harari and Liao,
2004) and the induction of T cell apoptosis (Rivoltini et al., 2002;
Jia et al., 2010). De Wilde et al. (2009) showed for the ﬁrst time
that another enzyme, heme oxygenase 1 (HO-1), is also associated
with suppressive function of MDSC. Indeed, endotoxin-induced
MDSC produce IL-10 and express HO-1, an enzyme involved in
the response to oxidative stress and featuring immunomodula-
tory and cytoprotective properties. Speciﬁc HO-1 inhibition by
tin protoporphyrin completely canceled suppression and IL-10
production by MDSC, showing the important role of this enzyme
in MDSC function.
In addition to their direct suppressive action, MDSC may
also have an indirect action on the inhibition of T lympho-
cyte proliferation by promoting the development of inducible
CD4+CD25+Foxp3+ T regulatory cells (iTreg; Huang et al., 2006).
The development of these Treg is independent from “classical”
MDSC suppressive mechanisms involving arginine metabolism,
but is linked to IL-10 plus TGF-β production. Moreover, prevent-
ingCD80 expressiononMDSCor theuse of anti-CTLA-4 antibod-
ies delay tumor growth, suggesting that CTLA-4/CD80 interaction
between MDSC and Treg is necessary for their activity or their
development (Yang et al., 2006). Another study analyzed the inter-
action of MDSC with macrophages in a mouse cancer model and
showed that, through IL-10 secretion, MDSC induced a type-2
polarization of macrophages which is characterized by a decrease
of IL-12 secretion and that promotes tumor growth (Sinha et al.,
2007b). IL-10 secretion by MDSC might also account for the Th2
deviation associated with MDSC activity (Sinha et al., 2007b). In
addition, cytotoxic T lymphocytes (CTL) cytotoxicity can be pre-
vented by MDSC through TGF-β production (Terabe et al., 2003).
More recently, RNS, and particularly peroxynitrites, emerged
as a key mediator of T cell function suppression by MDSC. Indeed,
peroxynitrites are a product of a chemical reaction between NO
and superoxide anion, and is one of the most powerful oxidiz-
ers. It induces amino acid nitration and nitrosylation such as
cysteine, methionine, tryptophan, and tyrosine (Vickers et al.,
1999). High levels of peroxynitrites have been found in areas
where inﬂammatory cells and MDSC accumulate. These high
levels of peroxynitrites have been also associated with tumor pro-
gression in many types of cancer (Vickers et al., 1999; Schmielau
and Finn, 2001; Mantovani et al., 2003; Szuster-Ciesielska et al.,
2004; Kusmartsev et al., 2005; Nagaraj et al., 2007) which have
been linked to the absence of T cell responses. One study indeed
reported the inﬁltration of differentiated but inactivated CD8+
T cells in prostate adenocarcinoma in human (Bronte et al., 2005).
It appears that the peroxynitrite production by MDSC during
direct contacts with T cells leads to TCR and CD8 molecule
nitration, changing the speciﬁc binding peptide of T cells and
making them intensive to speciﬁc antigen stimulation (Nagaraj
et al., 2007). Also, it has been shown that MDSC are able to
induceTCR/CD3ζ complex disruption through tyrosine nitrosyla-
tion/nitration, partly through NADPH oxidase 2 (NOX2) activity
(Nagaraj et al., 2010). This might explain some conﬂicting results
showing T cell function defects without modiﬁcation of CD3ζ
expression, especially since CD3ζ might be degraded later on
(Levey and Srivastava, 1995). Further, in tumor cells peptide bind-
ing to MHC class I can be prevented by MDSC-induced MHC
nitration through RNS production in a NOX2-dependent man-
ner (Lu et al., 2011). Another important factor that contributes
to suppressive activity of MDSC is the production of ROS. The
increase production of ROS has emerged as one of the main
features of MDSC in tumor-bearing mice and cancer patients
(Bronte et al., 2000; Schmielau and Finn, 2001; Mantovani et al.,
2003; Szuster-Ciesielska et al., 2004; Kusmartsev et al., 2005;
Agostinelli and Seiler, 2006; Youn et al., 2008), partly through
NOX2 activity (Corzo et al., 2009). In vitro inhibition of ROS
production by MDSC derived from these mice and patients com-
pletely cancels the suppressive effect of these cells (Bronte et al.,
2000; Schmielau and Finn, 2001; Szuster-Ciesielska et al., 2004).
Two other mechanisms of suppression have been recently iden-
tiﬁed. First, by expressing ADAM metallopeptidase domain 17
(ADAM17), MDSC induce the cleavage of L-selectin (CD62L)
ectodomain on T cells, a membrane molecule involved in the
migration of naïve T cells into lymph nodes. Thus, CD4 and CD8
cells become unable to migrate into lymph nodes or inﬂamma-
tory sites where they are supposed to be activated (Hanson et al.,
2009). Finally, two studies identiﬁed a new mechanism of suppres-
sion based on modulation of local amino acid metabolism and
homeostasis. This mechanism, shared with FoxP3+ Treg is called
cysteine/cystine deprivation (Yan et al., 2009, 2010). Some time
ago, it has been described that mammalian cells can obtain cys-
teine through three main pathways (Bannai, 1984). Foremost, they
can metabolize cysteine from methionine through transsulfura-
tion, a pathway catalyzed by cystathionase, a pyridoxal phosphate
dependent rate-limiting enzyme. Cells can also import cystine
(the oxidized form of cysteine) from the extracellular environ-
ment through the Xc− transporter that also exports glutamate
at the same time. Alternatively cells can import cysteine from
the extracellular environment through the alanine–serine–cysteine
(ASC) neutral amino acid transporter (that can also export cys-
teine). However, the ASC pathway is limited by the fact that
cysteine in the medium or in plasma, is predominantly present
under its oxidized form, cystine, which cannot use the ASC trans-
porter. Cysteine is a non-essential amino acid because it can
be produced through the transsulfuration pathway. However its
production is vital considering this is the limiting precursor in
the production of the tripeptide glutathione, the major intra-
cellular antioxidant molecule. In order to proliferate, T cells
need to produce glutathione in a sufﬁcient manner and thus
Frontiers in Immunology | Alloimmunity andTransplantation July 2012 | Volume 3 | Article 208 | 4
“ﬁmmu-03-00208” — 2012/7/14 — 20:11 — page 5 — #5
Dilek et al. Myeloid-derived suppressor cells in transplantation
need to replenish cysteine content to allow glutathione turnover
(Suthanthiran et al., 1990). They do express theASCneutral amino
acid transporter but are deﬁcient in cystathionase and Xc− trans-
porter. Of interest, Angelini et al. (2002) showed that after APC–T
cell interaction, APC allows the conversion of cystine into cysteine
in the medium, thereby providing cysteine in the reduced form
to T cells in order to proliferate. This is, in part, due to a process
involving APC import of cystine from the medium by the Xc−
transporter, followed by its intracellular reduction (i.e., the redox
potential being highly reduced inside cells) and by subsequent
export of cysteine through the ASC transporter. The model there-
fore presents APC as “feeder cells” for T cells, delivering cysteine
that otherwise would be lacking for T cell proliferation. Recently,
Srivastava et al. (2010) studied mouse MDSC in a tumor con-
text. They showed that MDSC express the Xc− transporter, but
lack the cystathionase enzyme and the ASC transporter. Thus,
MDSC seem to possess the same capacities as APC to import
cystine, but are unable to export cysteine and can therefore be
considered as “cystine/cysteine sinks.” Interestingly, by adding a
donor of cysteine, or a reducing agent (i.e., β-mercaptoethanol),
that allows conversion of cystine to cysteine in the medium, the
MDSC-induced T cells suppression was partially prevented, sug-
gesting indeed that MDSC inhibit T cell proliferation, in part,
by depleting the environment of cysteine (Srivastava et al., 2010).
Consistent with these results, by co culturing APC with MDSC,
Srivastava et al. (2010) observed reduced levels of extracellular cys-
teine contents as compared toAPCalone. All these results argue for
a new mechanism of suppression involving cysteine homeostasis:
MDSC may import cystine from the medium and induce cystine
starvation in the microenvironment (since they do not export it),
thus preventing APC from providing sufﬁcient cysteine for T cells
proliferation.
MDSC AND TRANSPLANTATION
In transplantation, in contrast with Treg, the role of MDSC is
not well characterized. It was ﬁrst described in a renal allograft
tolerance induction model in rats. In this model, tolerance was
induced by selective costimulation blockade (Dugast et al., 2008).
An accumulation of CD3−ClassII−CD11b+CD80/86+ cells was
observed in the blood of tolerant recipients and cells with a similar
phenotype were also detected into the tolerated graft. These cells
identiﬁed as MDSC inhibited proliferation of effector T cells and
induced a contact-dependent apoptosis in an iNOS-dependent
manner. The importance of iNOS was highlighted by the obser-
vation that administration of iNOS inhibitors induced rejection
of tolerated allograft. Another study showed that SHIP (inositol
polyphosphate-5-phosphatase) deﬁcient mice were able to accept
an allogeneic bone marrow transplant without developing GVHD.
SHIP is involved in the regulation of cell survival, proliferation,
and differentiation of myeloid cells as well as in the regulation
of MDSC homeostasis (Liu et al., 1999). Thereby, the inhibition
of GVHD in these SHIP−/− mice appears to be due to accu-
mulation of MDSC which suppress allogeneic T cell responses
(Ghansah et al., 2004; Paraiso et al., 2007). Also in mice, adop-
tive transfer of functional MDSC generated in vitro from murine
embryonic stem cells (ES) prevented GVHD via IL-10 and iNOS
and was able to induce the development of CD4+CD25+Foxp3+
Treg (Zhou et al., 2010). Likewise,Highﬁll et al. (2010) showed that
bone marrow-derived MDSC inhibited GVHD by an Arg1 depen-
dent mechanism, which itself is regulated by IL-13. There has also
been evidence that MDSC use the HO-1 to suppress alloreactivity
(De Wilde et al., 2009). In another mouse skin graft model, the in
vivo induction of Gr-1+CD11b+ MDSC by Neupogen, the recom-
binant human granulocyte colony-stimulating factor (rhG-CSF)
or the induction of CD4+Foxp3+ Treg by IL-2 complexes (IL-2C)
similarly prolonged allograft survival (Adeegbe et al., 2010). Inter-
estingly, when animals were treated with a combination of IL-2C
and Neupogen, a further increase of Treg was observed. This
observation suggested a possible cooperation between MDSC and
Treg to promote allograft survival. Such a MDSC–Treg cooper-
ation had also been studied in vitro: it was shown that MDSC
interaction with activated effector T cells resulted in the upreg-
ulation of iNOS and in the activation of the suppressive action
whereas interaction with activated Treg cells failed to upregulate
iNOS. As a result MDSC could block effector T cell prolifera-
tion but could not block proliferation of Treg cells (Dugast et al.,
2008). However, molecular interactions driving this differential
suppression on T effector and T regulatory cells have not been
elucidated.
Another mechanism of action of MDSC uncovered in the con-
text of transplantation involves the inhibitory receptors Ig-like
transcript 2 (ILT2), an inhibitory TCR whose activation causes a
decrease of T cell activation. In a model of skin allograft in mice,
ILT2 interaction with HLA-G was shown to induce expansion of
a MDSC population with a signiﬁcant suppressive activity (Zhang
et al., 2008). In addition, survival of skin allografts was prolonged
after adoptive transfer of MDSC from ILT2 transgenic mice. In
that case, MDSC accumulated into the graft. MDSC expansion
resulting from HLA-G/ILT2 interaction appeared to induce VEGF
and GM-CSF. ILT2 transgenic mice also have an increased expres-
sion of Arg1, probably due to IL-4 and IL-13 over-expression in
MDSC (Zhang et al., 2008).
MDSC can modulate rejection after pancreatic islets allografts
in diabetic mice (Marigo et al., 2010). Indeed adoptive transfer
of MDSC derived from bone marrow and generated by GM-
CSF and IL-6 increases signiﬁcantly the percentage of long-term
survival mice transplanted with allogeneic islets in the absence
of immunosuppression. Tolerance was achieved by inhibition
of IFN-γ producing T cells and was found dependent on the
expression by myeloid cells of regulatory transcription factor
CCAAT/enhancer binding protein beta (C/EBPβ), a downstream
target of Ras signaling involved in positive and negative cell cycle
regulation. Finally, in a mouse tolerance model of heart trans-
plantation, the group of Ochando showed increased numbers
of CD11b+CD115+Gr1+ monocytic MDSC. Shortly after trans-
plantation they migrated from the bone marrow to the transplant
where they participated in the induction of Treg and prevented ini-
tiation of adaptive immune responses (Garcia et al., 2010). Lastly,
elevated frequencies of circulating CD14Neg and CD14Pos MDSC
have recently been recorded in patients recipients of renal trans-
plants andCD14Neg MDSCwere found associatedwith occurrence
of squamous cell carcinoma in these patients (Hock et al., 2012).
Thus MDSC has potential functional relevance in kidney graft
recipients with respect to transplant tolerance but also cancer
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Table 1 | Reported involvement of MDSC in transplantation.
Phenotype Species Models Mechanisms Reference
CD3−ClassII−CD11b+CD80/86+ Rat Renal transplant tolerance Accumulation; iNOS Dugast et al. (2008)
Gr-1+CD11b+ Mouse GVHD inhibition Altered Ag processing by DC Ghansah et al. (2004), Paraiso et al. (2007)
CD115+Gr-1+F4/80+ Mouse GVHD prevention IL-10; iNOS Zhou et al. (2010)
CD11b+Ly6GlowLy6C+ Mouse GVHD inhibition Arg1 Highﬁll et al. (2010)
Gr-1+CD11b+ Mouse Skin allograft; long-term survival iNOS Adeegbe et al. (2010)
Gr-1+CD11b+ Mouse Skin allograft; long-term survival Arg1 Zhang et al. (2008)
Gr-1+CD11b+ IL-4Rα+ Mouse Islet allograft tolerance C/EBPβ factor; Arg1; iNOS Marigo et al. (2010)
Gr-1+CD115+CD11b+ Mouse Cardiac transplant tolerance IFN-γ-dependent pathways Garcia et al. (2010)
CD33+HLA-DR−CD11b+CD14+/− Human Renal transplantation Accumulation Hock et al. (2012)
immunosurveillance. The reported involvement of MDSC in
transplantation is summarized in Table 1.
In conclusion, probably due to their heterogeneous origin,
MDSC use several suppressive mechanisms which enable them
to control adaptive immune responses. In addition to their rec-
ognized role in tumor tolerance, they potentially exert a role in
the induction and maintenance of transplant tolerance. How-
ever, whether MDSC generated post-transplantation result from
creeping inﬂammation and interferes with immunosurveillance or
potentially constitute an appropriate immune regulatory response,
as recently explored (Hock et al., 2012), remains to be established.
Further phenotyping MDSC post-transplantation in humans
might help deciphering their potential “physiological” role and
understanding whether, in spite of their non-speciﬁc immuno-
suppressive activity, they might be used in cell therapies in synergy
with existing immunosuppressive therapies.
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